Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo
© 2020 MDPI AG. All rights reserved. Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Journal |
Published: |
2020
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85086687135&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70226 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-70226 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-702262020-10-14T08:47:15Z Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo Sariya Mapoung Shugo Suzuki Satoshi Fuji Aya Naiki-Ito Hiroyuki Kato Supachai Yodkeeree Natee Sakorn Chitchamai Ovatlarnporn Satoru Takahashi Pornngarm Limtrakul Pornngarm Limtrakul Biochemistry, Genetics and Molecular Biology Chemistry Pharmacology, Toxicology and Pharmaceutics © 2020 MDPI AG. All rights reserved. Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability. 2020-10-14T08:25:49Z 2020-10-14T08:25:49Z 2020-06-01 Journal 14203049 2-s2.0-85086687135 10.3390/molecules25122737 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85086687135&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70226 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Chiang Mai University Library |
collection |
CMU Intellectual Repository |
topic |
Biochemistry, Genetics and Molecular Biology Chemistry Pharmacology, Toxicology and Pharmaceutics |
spellingShingle |
Biochemistry, Genetics and Molecular Biology Chemistry Pharmacology, Toxicology and Pharmaceutics Sariya Mapoung Shugo Suzuki Satoshi Fuji Aya Naiki-Ito Hiroyuki Kato Supachai Yodkeeree Natee Sakorn Chitchamai Ovatlarnporn Satoru Takahashi Pornngarm Limtrakul Pornngarm Limtrakul Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo |
description |
© 2020 MDPI AG. All rights reserved. Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability. |
format |
Journal |
author |
Sariya Mapoung Shugo Suzuki Satoshi Fuji Aya Naiki-Ito Hiroyuki Kato Supachai Yodkeeree Natee Sakorn Chitchamai Ovatlarnporn Satoru Takahashi Pornngarm Limtrakul Pornngarm Limtrakul |
author_facet |
Sariya Mapoung Shugo Suzuki Satoshi Fuji Aya Naiki-Ito Hiroyuki Kato Supachai Yodkeeree Natee Sakorn Chitchamai Ovatlarnporn Satoru Takahashi Pornngarm Limtrakul Pornngarm Limtrakul |
author_sort |
Sariya Mapoung |
title |
Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo |
title_short |
Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo |
title_full |
Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo |
title_fullStr |
Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo |
title_full_unstemmed |
Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor in Vitro and in Vivo |
title_sort |
dehydrozingerone, a curcumin analog, as a potential anti-prostate cancer inhibitor in vitro and in vivo |
publishDate |
2020 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85086687135&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70226 |
_version_ |
1681752864155762688 |